Biotech companies got a boost in Japan on Friday as it was announced that SanBio will be listed publicly on the Tokyo Stock Exchange beginning April 8.
Japan's Asahi Kasei Pharma and U.K.-based Vernalis reached a second milestone on an undisclosed target for rheumatoid arthritis and other autoimmune diseases, which triggered a £500,000 payment to the British company.
Navidea Biopharmaceuticals is teaming up with European specialty pharma company Norgine to commercialize its Lymphoseek cancer diagnostic aid in Europe, looking to make a market splash as it drives international growth.
Hutchison China MediTech, based in Hong Kong, expects to file for its first drug approval next year for what it said would be the first modern drug developed in China since artemisinin was developed in the 1970s to treat malaria.
Denovo Biopharma will conduct clinical trials in China for its exclusively licensed pomaglumetad methionil, a late-stage neuroscience drug licensed from Eli Lilly.
Hanmi Pharmaceutical has licensed its poziotinib for treating several types of cancer to U.S.-based Spectrum Pharmaceuticals.
Taiwan's momentum as a biotech clinical trials hub in Asia remains strong, but valuations for listed biotech firms may not yet reflect a wide smart money view on eventual commercial prospects, according to Carl Firth, the CEO of Aslan Pharmaceuticals.
Laboratory equipment and services company PerkinElmer announced that it will provide Johnson & Johnson's new San Francisco life science incubator with on-site staff, training and scientific application support.
The Mayo Clinic and Gentag are partnering to develop next-generation, wireless, disposable patch sensors to enable researchers to track patient movements in order to better address conditions such as diabetes and obesity.
Alkahest, a member of Johnson & Johnson's just-launched biotech incubator, signed a $50 million agreement with Spanish giant Grifols to hit the gas on its novel approach to treating neurodegeneration.